Renaissance Technologies LLC Purchases 281,574 Shares of Voyager Therapeutics, Inc. $VYGR

Renaissance Technologies LLC grew its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 95.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 578,024 shares of the company’s stock after buying an additional 281,574 shares during the quarter. Renaissance Technologies LLC’s holdings in Voyager Therapeutics were worth $2,231,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in VYGR. Altshuler Shaham Ltd purchased a new position in shares of Voyager Therapeutics during the fourth quarter valued at $801,000. EcoR1 Capital LLC raised its stake in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after acquiring an additional 3,332,544 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $44,000. Privium Fund Management B.V. raised its stake in Voyager Therapeutics by 111.1% in the fourth quarter. Privium Fund Management B.V. now owns 95,000 shares of the company’s stock valued at $373,000 after buying an additional 50,000 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Voyager Therapeutics during the 3rd quarter worth approximately $93,000. Institutional investors own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

VYGR has been the subject of a number of research reports. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Stock Down 3.1%

Shares of Voyager Therapeutics stock opened at $3.17 on Tuesday. The firm has a market cap of $191.53 million, a PE ratio of -1.76 and a beta of 1.31. Voyager Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $5.55. The business has a 50-day moving average price of $3.39 and a 200 day moving average price of $3.73.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative return on equity of 54.82% and a negative net margin of 312.63%.The company had revenue of $3.17 million for the quarter, compared to the consensus estimate of $4.52 million. On average, sell-side analysts expect that Voyager Therapeutics, Inc. will post -1.43 EPS for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.